Autolus Therapeutics (AUTL) Receivables - Other (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Receivables - Other data on file, last reported at $915000.0 in Q4 2025.

• Quarterly Receivables - Other rose 86.35% year-over-year to $915000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $915000.0 (up 86.35% YoY) and the FY2025 annual result came in at $915000.0, down 35.61% from the prior year.
• Receivables - Other slipped to $915000.0 in Q4 2025, from $936000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $10.7 million in Q3 2021 to a low of $257000.0 in Q1 2021.
• A 5-year average of $1.4 million and a median of $700500.0 in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2021 — Receivables - Other jumped 1249.37% — and 2022, when it sank 97.46%.
• Tracing AUTL's Receivables - Other over 5 years: stood at $271000.0 in 2021, then jumped by 429.52% to $1.4 million in 2022, then slumped by 64.04% to $516000.0 in 2023, then retreated by 4.84% to $491000.0 in 2024, then jumped by 86.35% to $915000.0 in 2025.
• The last three Receivables - Other figures came in at $915000.0 (Q4 2025), $936000.0 (Q3 2025), and $665000.0 (Q2 2025), per Business Quant data.